Cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately five collaborative projects that aim to rapidly identify new […]

The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).  KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered via a nebuliser.   By inducing […]

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer. Amid continued concern about antibiotic resistance, the headline news this week was the discovery […]

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer and reflects the vital importance of collaboration, partnership and support within this industry. Partnerships […]

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships have been forged and renewed to shed light on neuropsychiatric disorders, oncology and cystic fibrosis. Meanwhile, Ochre Bio successfully raised […]

LifeArc, a national medical research charity, is joining the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate in a strategic partnership alongside Cystic Fibrosis Trust and Medicines Discovery Catapult (MDC). The CF AMR Syndicate aims to address unmet patient needs by linking people with CF with leading experts across industry, academia and the NHS.  Together, this […]

Biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation to help the company advance its lead compound for cystic fibrosis patients who have been infected with methicillin-resistant Staphylococcus aureus (MRSA).  Destiny Pharma will establish a research project with the Cystic Fibrosis Foundation where it will establish the potential of its XF-73 drug as […]